Cargando…

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD

BACKGROUND: In neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neutrophils are found in CNS lesions. We previously demonstrated that NMOSD neutrophils show functional deficiencies. Thus, we hypothesized that neutrophil accu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroeder-Castagno, Maria, Del Rio-Serrato, Alba, Wilhelm, Andreas, Romero-Suárez, Silvina, Schindler, Patrick, Alvarez-González, Cesar, Duchow, Ankelien-Solveig, Bellmann-Strobl, Judith, Ruprecht, Klemens, Hastermann, Maria, Grütz, Gerald, Wildemann, Brigitte, Jarius, Sven, Schmitz-Hübsch, Tanja, Paul, Friedemann, Infante-Duarte, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526338/ https://www.ncbi.nlm.nih.gov/pubmed/36183103 http://dx.doi.org/10.1186/s12974-022-02600-0

Ejemplares similares

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
por: Finke, Carsten, et al.
Publicado: (2016)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
por: Pache, Florence, et al.
Publicado: (2016)

Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study
por: Sperber, Pia S., et al.
Publicado: (2022)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

Structure–function correlates of vision loss in neuromyelitis optica spectrum disorders
por: Gigengack, Norman K., et al.
Publicado: (2022)

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
por: Jarius, Sven, et al.
Publicado: (2014)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders
por: Ayadi, Noah, et al.
Publicado: (2021)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
por: Ostendorf, Lennard, et al.
Publicado: (2021)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Contemporary management challenges in seropositive NMOSD
por: Costello, Fiona, et al.
Publicado: (2022)

Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
por: Oertel, Frederike C., et al.
Publicado: (2019)

The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON
por: Yao, Yajun, et al.
Publicado: (2022)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) und Anti-Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankungen (MOGAD)
por: Seifert-Held, Thomas
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2dan0dm3pi9i7h037fakm3qjb